Computational Study of Thrombus Formation and Clotting Factor Effects under Venous Flow Conditions  by Govindarajan, Vijay et al.
ArticleComputational Study of Thrombus Formation and
Clotting Factor Effects under Venous Flow
ConditionsVijay Govindarajan,1 Vineet Rakesh,1 Jaques Reifman,1,* and Alexander Y. Mitrophanov1
1Department of Defense Biotechnology High Performance Computing Software Applications Institute, Telemedicine and Advanced
Technology Research Center, U.S. Army Medical Research and Materiel Command, Fort Detrick, MarylandABSTRACT A comprehensive understanding of thrombus formation as a physicochemical process that has evolved to protect
the integrity of the human vasculature is critical to our ability to predict and control pathological states caused by amalfunctioning
blood coagulation system. Despite numerous investigations, the spatial and temporal details of thrombus growth as a multicom-
ponent process are not fully understood. Here, we used computational modeling to investigate the temporal changes in the
spatial distributions of the key enzymatic (i.e., thrombin) and structural (i.e., platelets and fibrin) components within a growing
thrombus. Moreover, we investigated the interplay between clot structure and its mechanical properties, such as hydraulic resis-
tance to flow. Our model relied on the coupling of computational fluid dynamics and biochemical kinetics, and was validated
using flow-chamber data from a previous experimental study. The model allowed us to identify the distinct patterns character-
izing the spatial distributions of thrombin, platelets, and fibrin accumulating within a thrombus. Our modeling results suggested
that under the simulated conditions, thrombin kinetics was determined predominantly by prothrombinase. Furthermore, our
simulations showed that thrombus resistance imparted by fibrin was ~30-fold higher than that imparted by platelets. Yet,
thrombus-mediated bloodflow occlusion was driven primarily by the platelet deposition process, because the height of the
platelet accumulation domain was approximately twice that of the fibrin accumulation domain. Fibrinogen supplementation in
normal blood resulted in a nonlinear increase in thrombus resistance, and for a supplemented fibrinogen level of 48%, the
thrombus resistance increased by ~2.7-fold. Finally, our model predicted that restoring the normal levels of clotting factors II,
IX, and X while simultaneously restoring fibrinogen (to 88% of its normal level) in diluted blood can restore fibrin generation
to ~78% of its normal level and hence improve clot formation under dilution.INTRODUCTIONThe blood coagulation system is the first line of the human
body’s defense against vascular injuries (1–4). When a
blood vessel is breached, a complex array of molecular
and cellular reactions leads to the formation of a
thrombus—a spatial structure consisting mainly of small
blood cells (platelets) and the fibrous protein fibrin, which
covers the site of injury and stops the hemorrhage (i.e.,
effects hemostasis). However, this normal hemostatic
response may be insufficient in the case of severe injuries,
when the naturally forming hemostatic thrombi do not
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creativecommons.org/licenses/by-nc-nd/4.0/).from large blood vessels. Moreover, severe trauma may lead
to pathological changes (collectively known as trauma-
induced coagulopathy (5)) that decrease the blood clotting
potential in the trauma victim. Sometimes, genetic defects
(e.g., hemophilia (2)) may decrease the clotting potential.
Furthermore, pathological thrombi can form inside intact
blood vessels, thereby occluding the blood flow in otherwise
healthy tissues (i.e., causing thrombosis (4,6)). To predict
and prevent such pathological conditions, or to reverse
them using therapeutic interventions, a detailed mechanistic
understanding of the thrombus formation process is needed.
Platelets and fibrin are the main structural components of
a hemostatic thrombus (1,2,4,7,8). Fibrin is produced when
its precursor, fibrinogen, is cleaved by the enzyme thrombin,
which in turn is generated in a complex sequence of
biochemical reactions when thrombus formation is initiated.
The role of fibrin is to increase the mechanical stability of
the growing thrombus by ‘‘tying together’’ the aggregatedBiophysical Journal 110, 1869–1885, April 26, 2016 1869
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thrombus formation (4,8,9). The critical role of fibrin in vivo
is illustrated by clinical cases involving patients with an in-
herited fibrinogen deficiency, who are prone to bleeding and
need fibrinogen supplementation (10). Moreover, fibrinogen
deficiency can occur as a result of trauma, and the use of
fibrinogen blood supplements in trauma has been the subject
of recent investigations (5). Fibrinogen supplementation
during surgery has been shown to reduce postoperative
bleeding (11). At the same time, elevated fibrinogen levels
may contribute to the development of thrombosis (4,6,12).
Quantitative knowledge about the interactions between
fibrin and other clot components may allow us to achieve
the desired balance in fibrinogen- and fibrin-mediated mod-
ulation of blood coagulation.
Fibrin biochemistry, structural biology, and rheology
have been extensively investigated. Such studies provide in-
formation about the biochemical reactions leading to fibrin
formation and polymerization, constituting molecular
‘‘parts’’ and three-dimensional shapes of fibrin fibers, as
well as information about the physical properties of fibrin,
such as its viscoelasticity (4,8,9,13,14). However, the details
of fibrin accumulation as a spatiotemporal process remain
elusive, and this lack of knowledge limits our understanding
of the thrombus as a spatial structure whose composition
may vary with time. Specifically, it is not clear how the
spatial distribution of deposited platelets, thrombin, and
fibrin can change in the course of thrombus development.
More research is needed to understand the relative contribu-
tions of platelets and fibrin to the growing hydraulic resis-
tance of the thrombus, and to the corresponding changes
in blood flow. Finally, it is not known how the spatial distri-
bution of fibrin in the clot, and the fibrin-associated mechan-
ical properties of the clot, are modified in response to
changes in the overall availability of fibrinogen and fibrin
in the system. Here, we attempted to provide insights into
these fundamental questions.
Blood coagulation has traditionally been studied using
three approaches: in vitro experiments, in vivo experiments,
and clinical investigations. Although these approaches pro-
vide valuable information about the blood-clotting process,
each has its limitations. The recent emergence of systems
biology has suggested a way to circumvent some of the lim-
itations of traditional experimentation by combining exper-
imental studies with the use of mathematical models
(15,16). Such models can be designed to represent the
mechanisms of the human blood coagulation process in
realistic blood-flow conditions and vessel geometries, and
can provide a flexible means to rapidly investigate a wide
range of plausible thrombus formation scenarios. As such,
these models can be practically useful when they are
applied to predict drug targets and the effects of pharmaco-
logical intervention as a function of intervention time and
drug dosage. Here, we use a computational systems biology
approach to investigate fibrin accumulation as a spatiotem-1870 Biophysical Journal 110, 1869–1885, April 26, 2016poral process during thrombus development in flowing
blood.
The existing literature contains numerous examples of
computational modeling of some aspects of blood coagula-
tion under flow (15–30). However, previous modeling ef-
forts did not focus on the investigation of relative
contributions of platelets and fibrin to spatial thrombus
growth. We developed and applied a model of thrombus for-
mation under flow that captured the interplay of platelet
deposition, complex thrombin-generation biochemistry,
and fibrin formation and function, and was able to predict
essential dynamic features of the thrombus formation pro-
cess observed in flow-chamber experiments (31–33). Using
the model, we elucidated the distinct spatial distributions of
platelets, thrombin, and fibrin within the thrombus. More-
over, the model predicted that the occlusion of a flow-cham-
ber channel by a growing thrombus is primarily driven by
platelet deposition. Furthermore, in our modeling studies,
we established that fibrinogen supplementation affects
thrombus properties in a nonlinear fashion in the cases of
both normal blood composition and diluted blood, which
represents the conditions of dilution/consumption-induced
coagulopathy that occur during trauma and surgery. Finally,
the model predicted that supplementation with fibrinogen
and with a prothrombin complex concentrate (PCC) can
potentially improve the fibrin generation and accumulation
kinetics in diluted blood, thereby improving clot formation.MATERIALS AND METHODS
We developed a computational model that represents thrombus formation in
a straight channel; this model was used in all the simulations described in
this work. The model was implemented using the computational fluid dy-
namics package FLUENT v. 14.5 (ANSYS, Canonsburg, PA). Below is a
description of the key model features; additional details, such as a full set
of the model equations and a definition of our variable (i.e., shear-depen-
dent) platelet adhesion rate constant, are provided in the Supporting Mate-
rial. All of the model’s parameter values were taken from literature data
except for the maximal platelet density and platelet adhesion rate constant.
The latter two parameters were fine-tuned to improve our model’s quanti-
tative accuracy with respect to the analyzed platelet deposition data, as
described in the Supporting Material.Model of the thrombus formation mechanism:
platelet deposition and the biochemical
coagulation network
The formation of a thrombus inside a blood vessel is manifested through the
deposition and activation of platelets at the site of vascular injury and through
thrombin-catalyzed fibrin generation. These complex processes are concur-
rent and interdependent,with the biochemical thrombingeneration andfibrin
formation network comprising dozens of intermediate biochemical species
and reactions (Fig. 1). Our platelet activation model and the biochemical
network model are modified versions of those developed by Leiderman
and Fogelson (22). The SupportingMaterial includes a complete description
of the platelet dynamics and biochemical reactions, together with the initial
conditions and values of the kinetic constants (Eqs. S1–S55 and Tables S1–
S8). In what follows, we provide a summarized description of the system.
FIGURE 1 Schematic of the biochemical
network represented in our model of blood coagula-
tion. Coagulation reactions begin when blood leak-
ing from a breached vessel comes into contact with
the tissue factor (TF) expressed extravascularly.
Colored arrows show the type of reaction, as indi-
cated in the legend. Reactions shown inside the
gray sphere are the platelet-surface reactions, and
reactions outside the gray sphere are the reactions
taking place in the blood plasma. The biochemical
blood coagulation network comprises zymogens,
proteolytic enzymes, and their cofactors. Among
the key proteins (in an inactive form) are the factors
V, VII, VIII, IX, X, and II (prothrombin). Their
active counterparts are designated with the suffix
‘‘a.’’ Reactions begin when TF is exposed to the
flowing blood and binds with factor VIIa to form
the TF:VIIa complex (extrinsic tenase). This is fol-
lowed by the activation of factors IX and X to IXa
and Xa, respectively, by TF:VIIa. Factor Xa in
plasma activates plasma prothrombin to form trace
amounts of factor IIa (thrombin). Platelet-bound
factor Xa activates factors V and VIII to form fac-
tors Va and VIIIa, respectively. Factor IXa binds
with factor VIIIa on the activated platelet surface to form the complex IXa:VIIIa (intrinsic tenase). Factor Xa binds with factor Va on the surfaces of activated
platelets to form the complex Xa:Va (prothrombinase). Extrinsic and intrinsic tenases activate factor X to Xa, with intrinsic tenase acting as the main acti-
vator. Prothrombinase activates platelet-bound prothrombin to thrombin, which in turn performs several functions essential for efficient blood coagulation.
Thrombin activates factors Vand VIII, both on the surface of activated platelets and in plasma. This promotes the formation of intrinsic tenase and prothrom-
binase, acting as a positive feedback loop increasing thrombin generation. Importantly, thrombin converts fibrinogen to fibrin, which stabilizes the thrombus.
The natural anticoagulation mechanisms (i.e., the TF pathway inhibitor and antithrombin III) negatively regulate thrombin generation and activity. The inhib-
itory protein antithrombin III (ATIII) inactivates several enzymes in the coagulation system, namely, factors IIa, Xa, and IXa, whereas the TF pathway in-
hibitor (TFPI) inhibits the TF:VIIa complex. To see this figure in color, go online.
Modeling Thrombus Formation under FlowThrombus formation begins when platelets bind to collagen exposed at
the site of vascular injury. Such binding leads to platelet activation, as a
result of which platelet membranes acquire the ability to provide catalytic
support for the biochemical reactions that lead to thrombin formation
(Fig. 1). Thrombin itself is a potent platelet activator, which is reflected
in our model. Platelets undergo transformations and interactions with
each other that are governed by their evolution equations (Eqs. S1–S5).
Briefly, when there are no external stimuli, platelets remain mobile and
inactive (i.e., in the ‘‘resting’’ state). The mobile platelet types can convect,
as determined by the fluid velocity field, and diffuse through the flow. Acti-
vated platelets can either stay mobile (i.e., able to convect and diffuse) or
can bind with other bound and activated platelets or with the collagen
exposed at the injury site (or at a thrombogenic surface), thereby becoming
immobile. Activated platelets have the ability to accelerate the biochemical
reactions (Fig. 1) occurring on their surfaces, and these biochemical reac-
tions ultimately lead to thrombin generation.
The major differences between the biochemical network model used in
this work and that in the original Leiderman-Fogelson (LF) model (22)
are as follows. First, we have included a representation of the conversion
of fibrinogen to fibrin (34) and a model for the impact of fibrin on thrombus
formation. Representation of fibrin, which reinforces the mechanical bonds
between platelets, is important, because it is generally considered essential
for thrombus stability (4,8,31). Second, we have incorporated protein-spe-
cific binding-site numbers for zymogens and enzymes binding to platelet
surfaces, with prothrombin and factor X sharing the binding sites (the de-
tails are provided in the Supporting Material). Third, we have included
the activation of prothrombin to thrombin by the action of factor Xa in
plasma (35). Finally, we omitted explicit representation of some intermedi-
ate enzyme-substrate complexes reflected in the LF model, which resulted
in a reduction in the total number of model equations. This simplification
assumes that the intermediate complexes are sufficiently short-lived; how-ever, we explicitly represented all initial substrates and final products of the
overall reaction,which are expected to perform a biological function of inter-
est. It is consistent with themodeling approach in the biochemically rigorous
and widely used Hockin-Mann model of thrombin generation (36). It has
been recommended that simplified biochemical models should be used in
conjunction with computational fluid dynamics flow modeling, especially
when geometries for large blood vessels (e.g., coronary arteries) are involved
(37). These considerations reinforced our decision to simplify the biochem-
ical reactions in our model, because it was our intention to develop a model
that allows for future extensions to perform full three-dimensional (3D) sim-
ulations for realistic, subject-specific vessel geometries.Transport of platelets and coagulation proteins
The spatiotemporal kinetics of the biochemical species included in the
model are governed by the convection-diffusion-reaction equation. The
general form of this equation for a given species i is
v½Ci 
vt
¼ V , ð~u½CiÞ þ V , ðDiV½CiÞ þ Ri; (1)
where ½Ci denotes the concentration of species i, ~u denotes the fluid
velocity vector (each biochemical species has the same velocity as its
surrounding fluid), and Di represents the individual species diffusivity.
We implemented interactions, such as platelet and protein activation and
protein depletion, using the source term Ri and chose a second-order up-
wind scheme to discretize the convection-diffusion-reaction equation (38)
with a convergence criterion of 106.
In a tube-like flow chamber or a blood vessel, red blood cells have a ten-
dency to aggregate in the center, thus forming a core (39). In addition, the
biconcave-shaped red blood cells exhibit a tank-treading and tumblingBiophysical Journal 110, 1869–1885, April 26, 2016 1871
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rate (40). This increases the effective diffusivity of the platelets and the
plasma proteins. Hence, the diffusivity term in Eq. 1 should account for
both the Brownian motion in blood plasma and the effect of red blood cells.
To this end, we implemented the enhanced diffusivity model proposed by
Zydney and Colton (41):
Dei ¼ Dbi þ kd2rbc4ð1 4Þh _g; (2)
where Dei and D
b
i denote the enhanced diffusivity and Brownian diffusivity,
respectively, of species i, k and h represent empirical constants, drbc denotes
the red-blood-cell diameter, 4 represents the local hematocrit, which varies
along the height of the flow-chamber channel, and _g denotes the local shear
rate. We used the following definition for 4 (the so-called ‘‘blunt’’ hemat-
ocrit profile, which gives an improved agreement with experimental data
in comparison to other profiles (42)):
4 ¼ 4b
2

1 cospy
d

; (3)
where 4b denotes the bulk hematocrit, y denotes the distance from the chan-
nel wall, and d represents the thickness of the cell-free layer. We chose the
latter to be 10% of the channel height, so that the hematocrit profile defined
by Eq. 3 matched that of Hund and Antaki (42).
Besides enhancing diffusivity, the motion of red blood cells results in a
nonuniform platelet distribution, with platelets tending to move toward
the periphery of the blood flow. This effect is commonly called platelet
margination and results in an increased platelet concentration near the
wall (43–46). Platelet margination can be modeled by combining the
expression for diffusivity with a potential function in the platelet-
transport-governing equation (Eq. S1). The lateral drift of the platelets
is then directed by the gradients of this potential (43,45,47). This takes
into account the effect of the local hematocrit level on platelet margin-
ation (42,43,45,47). Models based on other simulation techniques,
such as a combination of a master equation model of suspension dy-
namics and hydrodynamic Monte Carlo (48,49), explicit representation
of red blood cells using a fixed red-blood-cell distribution (46), and
deformable red blood cells based on the lattice-Boltzmann-immersed-
boundary method (44), have also been developed to study platelet
margination.
To capture platelet margination effects in our study, we implemented the
platelet margination model developed by Bark and Ku (43) (see Eqs. 4 and
5 below). We chose this particular model because it showed that when used
together with the enhanced diffusivity model from (41), this platelet
margination model accurately captured the experimentally observed
platelet flux for shear rates <6000 s1 (43). Moreover, this platelet margin-
ation model is naturally compatible with, and could be directly integrated
in, our overall modeling framework. The equations describing the platelet
flux are
~Np ¼ ~uCp  DepVjp; (4)
Vjp ¼ CpVð4Þ þ 4V

Cp

; (5)where~Np denotes the platelet flux,Cp denotes the platelet concentration,D
e
p
represents the enhanced diffusivity introduced in Eq. 2, and jp represents
the platelet field potential, which is defined as a function of the local hemat-
ocrit level, 4 (with a blunt inlet concentration profile, as described in Eq. 3,
which is similar to the one used in (42) and (43)). The term CpVð4Þ serves
as the drift function, which enables platelets to move down the red-blood-
cell gradient in the direction that is a function of the platelet concentration.
The enhanced diffusivity determines the platelet transport rate, whereas the
potential in Eqs. 4 and 5 drives platelets in a specific direction based on the
gradients of red blood cells and platelets in the flow (43).1872 Biophysical Journal 110, 1869–1885, April 26, 2016Modeling the effect of a growing thrombus on
blood flow
Blood flow in our model is governed by the incompressible Navier-Stokes
equation. The effect of a thrombus on the blood flow is represented via a
reduction of fluid velocity in the region occupied by the growing thrombus,
as detailed below. The thrombus is represented by a growing porous me-
dium whose permeability depends on the increasing fractions of deposited
platelets and the fibrin concentration. This is achieved by incorporating
additional source terms into the Navier-Stokes equation, as follows:
V , ð~uÞ ¼ 0; (6)

v~u

mr
vt
þ ð~u ,VÞ~u ¼ Vpþ mD~u
KtðxÞ~u; (7)
where ~u denotes the fluid velocity vector, r represents the blood den-
sity, p represents the fluid pressure, m denotes the dynamic viscosity of
blood, and the term m=KtðxÞ in Eq. 7 is known as the Brinkman term,
where KtðxÞ, which depends on the space point x; represents the perme-
ability of a porous medium and 1=KtðxÞ represents its hydraulic resis-
tance (50).
To solve the Navier-Stokes equation (Eqs. 6 and 7), we employed the
PISO (i.e., pressure implicit with splitting of operators) algorithm available
in FLUENT to couple the velocity and the pressure. We chose PISO over
other schemes because, in addition to producing stable results, it allows
the use of large time steps in unsteady flow problems (51). The second-
order upwind scheme is used for the spatial discretization of the momentum
equation (Eq. 7). The pressure interpolation was performed using the ‘‘pres-
sure staggering’’ option (PRESTO!) (52). The PRESTO scheme uses the
discrete continuity balance for the staggered control volume to compute
the pressure. This procedure, implemented in FLUENT, is similar to the
staggered-grid scheme used with structured meshes (52,53). Numerical
convergence was achieved by setting a convergence criterion of 106 for
continuity and velocity, and the solution was iterated until convergence
of each time step. We used the algebraic multigrid method (AMG) with
BCGSTAB (i.e., the biconjugate gradient stabilized method) stabilization
available in FLUENT to achieve a faster and smoother convergence during
the iterative procedure (54). Under-relaxation factors of 0.3, 0.7, and 1.0
were used for pressure, momentum, and the concentrations of all biochem-
ical species, respectively.
In our model, the hydraulic resistance is imparted by the deposited plate-
lets and fibrin. The individual contributions of hydraulic resistances from
platelets and fibrin are added (55,56), and 1=Kt in Eq. 7 is expressed as
1
Kt
¼ 1
Kp
þ 1
Kf
; (8)
where Kp and Kf are the permeability of platelet and fibrin mass,
respectively.
We computed the contribution of the platelets to the total hydraulic resis-
tance as (22)
1
Kp
¼ amax
 
ð4bÞ2
4bo
2 þ ð4bÞ2
!
; (9)
where 4b denotes the fraction of bound platelets, which is the ratio of
bound platelets to the maximal possible platelet density, and 4b0 is a con-
stant; when 4b ¼ 4b0, the frictional resistance reaches half of its maximal
value. Leiderman and Fogelson (22) estimated amax (inverse permeability)
to be sixfold larger than the values observed in old thrombi extracted from
abdominal aortic aneurysms, which had a permeability value of 0.91 5
0.54 mm4 N1 s1 (57).
Modeling Thrombus Formation under FlowIn the thrombus, fibrin is naturally present in a polymeric state, which
reduces its mobility under flow (58). Because fibrin polymerization is not
explicitly represented in our model, we accounted for fibrin’s reduced
mobility by assuming that it cannot convect with the flow. It should be
noted that although fibrin can diffuse in the domain, its diffusion is
comparatively slow; indeed, its diffusion coefficient is the lowest among
all the modeled species (34) (Table S1). To predict the hydraulic resistance
imparted by fibrin, we used the Davies equation (59), which has often
been used to estimate the permeability of fibrin gels and blood clots
(30,56,60–62):
1
Kf
¼
1641:5f

1þ 5643f

a2f
; (10)
where af denotes the fiber radius and 4f denotes the ratio of the fibrin con-
centration to that of fibrinogen. Fibrin permeability values predicted using
the Davies equation were in reasonable agreement with experimental mea-
surements (56).Modeling blood dilution and supplementation
with fibrinogen and a prothombin complex
concentrate
To represent blood dilution, we followed our previous work and used an
unequal blood dilution model, in which different coagulation factors are
diluted to different degrees (63). This model was based on an in vivo
porcine model of dilution-induced coagulopathy (64). In our model, dilu-
tion was implemented by reducing the initial concentrations of coagulation
proteins by the appropriate amounts (see Table S9); these amounts were
derived from our previous work (63,65). The diluted concentration for
fibrinogen was chosen to be 40% of the normal level, which is consistent
with in vivo data (64). Note that platelets were not diluted, so as to reflect
the compensatory platelet resupply (e.g., from the spleen into the blood-
stream) expected to occur in vivo (63). To represent the supplementation
with a PCC, which is a combination of procoagulant clotting factors aimed
at enhancing thrombin generation, we restored the corresponding PCCare the flow boundary conditions used in our simulations. The notation U¼ 0, V
where U and V denote the x and y velocity components, respectively. To see thcomponents (i.e., coagulation factors FII, FIX, and FX used in a typical
three-factor PCC (66)) to their undiluted levels (see Table S9), in accor-
dance with our previous work (65).Simulated flow conditions
We simulated thrombus formation in a channel of the eight-channel pres-
sure-relief flow chamber described by Maloney et al. (67) and Colace
et al. (31). Fig. 2 A shows a photograph of the flow chamber and the compu-
tational domain used in our thrombus formation simulations. Fig. 2 B shows
the 3D geometry of the flow-chamber section consisting of two channels
measuring 250  60 mm (base  height) at their cross section. In the
two-dimensional (2D) representation of the flow chamber (Fig. 2 C), two
channels, each measuring 60 mm in height, are stacked one above the other,
which allows us to perform the ‘‘pressure relief’’ mode simulations in a 2D
setting (31). Thrombus formation was initiated in one of the two channels,
which contained a thrombogenic surface coated with tissue factor (TF) and
collagen. Imaging of the thrombogenic patch led us to estimate the tissue
factor surface coverage as 10 molecules/mm2 (31).
The 2D flow domain analyzed in this study consisted of two separate in-
lets and a single outlet with corresponding boundary conditions (Fig. 2 C).
We simulated the pressure-relief mode (introduced in (31)) by defining a
constant-pressure (i.e., atmospheric pressure) boundary condition at the
inlet and a constant flow rate of 4 mL/min at the outlet, which corresponds
to an initial wall shear rate of 200 s1. Because Colace et al. (31) used
whole blood in their flow-chamber experiments, we chose a hematocrit
value of 0.4, a typical value for this parameter. These settings make our
simulation consistent with their experimental conditions. The simulation
covered a 430-s time interval with a 0.01-s time step. A no-slip and
no-penetration condition was imposed at the flow-chamber walls. In our
simulations, thrombus formation was initiated in one of the channels at a
250-mm-long thrombogenic strip (Fig. 2 C), with TF levels matching the
experimental setup (31). The initial concentrations (Table S3) of the coag-
ulation proteins were taken from the experimental literature and adjusted
to represent whole-blood concentrations. To describe the expected, nonuni-
form distribution of platelets over the channel’s cross section, we used the
near-wall platelet concentration profile defined in Eckstein et al. (68) with a
peak/center ratio of 8.00. We used this profile to define the inlet profile forFIGURE 2 Two-dimensional (2D) geometric
representation of the flow chamber. (A) Photograph
of the overall setup of the flow chamber (image re-
produced with permission from Colace et al. (31)).
Thrombus formation is initiated when blood flows
over a thrombogenic surface in the chamber’s chan-
nels. Under the pressure-relief mode, one of the
channels is coated with a thrombogenic surface.
When a thrombus begins to occlude the channel,
blood flow is increased in the thrombus-free chan-
nel to maintain a constant outflow (withdrawn from
a syringe at the outlet) (31). (B) Three-dimensional
geometry of the flow-chamber section that consists
of two separate inlets and a single outlet. The di-
mensions of the channels are as indicated in the
figure. (C) The geometry of the flow chamber
was constructed to provide a 2D representation
(as in (31)). This 2D geometry was constructed so
that it maintained a channel height of 60 mm. The
channel without a thrombogenic surface is stacked
above the channel with one. This reconstructed ge-
ometry allowed us to perform simulations in the
pressure-relief mode in a 2D setting. Also indicated
¼ 0 reflects the no-slip and no-penetration conditions imposed on the walls,
is figure in color, go online.
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uniform mesh size of 1.875 mm, which is adequate for resolving the species
transport and flow (22).FIGURE 3 The computational model captures the dynamics of thrombus
growth. (A) Model-predicted and experimentally measured platelet accu-
mulation. The solid line (no symbols) shows the normalized model-pre-
dicted values of the integral of the concentrations of bound platelets
calculated over the entire flow domain. The solid line with square markers
shows normalized platelet fluorescence intensity, which represents platelet
accumulation observed in the flow-chamber experiment (31). Data points,
represented by the markers, were connected with solid lines to enhance
the visual representation of the displayed trends. To facilitate data compar-
isons, the model-generated and experimental data were independently
normalized to their corresponding maximal values. (B) Spatial distribution
of the deposited platelets at 430 s. The bottom panel shows an enlargement
of the model-predicted platelet deposition domain. The experimentally
measured platelet accumulation (data extracted from Fig. 7 B in (31)) is
indicated by the black line superimposed over the color image. The vertical
white dashed lines indicate the beginning and end of the thrombogenic
surface. (C) Spatial distribution of the deposited fibrin at 430 s. The exper-
imentally measured fibrin accumulation (data extracted from Fig. 7 C in
(31)) is indicated by the black line superimposed over the color image.
The vertical white dashed lines indicate the beginning and end of the throm-
bogenic surface. To see this figure in color, go online.RESULTS
Modeling predicts essential kinetic features of
thrombus formation
The model-predicted time course of platelet deposition
initiated by the thrombogenic surface was consistent with
the platelet accumulation data presented in Colace et al.
(31), which show an approximately linear time dependence
(Fig. 3 A). As expected, activated and bound platelets
continued to accumulate at the thrombogenic surface
throughout the simulation, and the predicted height of the
platelet deposition domain at 430 s was ~39 mm at the up-
stream and downstream sides of the thrombogenic surface
and ~32 mm at the middle (Fig. 3 B, bottom). Interestingly,
the simulated spatial distribution of the accumulated plate-
lets extended beyond the upstream and downstream edges
of the thrombogenic surface (Fig. 3 B), which is in accord
with experimental observations (see Fig. 7 B in (31)). Fibrin
was produced over the thrombogenic surface simulta-
neously with platelet deposition, and the predicted height
for fibrin deposition reached ~16 mm at 430 s (Fig. 3 C).
The spatial boundaries of the model-predicted platelet-
and fibrin-deposition domains were in reasonable agreement
with those determined experimentally (Fig. 3 B, bottom, and
Fig. 3 C, respectively).
In our model, fibrin generation depends on thrombin
generation, which dynamically changes during thrombus
growth. During the initial 220 s of the simulation, very little
thrombin (and, therefore, little fibrin) was generated in the
flow chamber; this was followed by a sharp, nonlinear rise
in the thrombin concentration (Fig. 4 A). This thrombin
burst thus appeared to be responsible for generating the
bulk of fibrin in the growing thrombus. Indeed, after an
initial lag phase, our model showed a rapid nonlinear in-
crease in fibrin production that followed the rise in thrombin
generation (Fig. 4 B). Although the model-predicted platelet
deposition kinetics and the spatial boundary of the thrombus
(i.e., bound platelets and fibrin) compared reasonably well
with the experiment of Colace et al. (31) (Fig. 3, B and
C), our model did not capture the temporal dependence of
fibrin accumulation from that work (see Fig. 4 B), which
shows the normalized integral of the model-predicted fibrin
concentration calculated over the entire flow domain). In
contrast to our findings, that experimental work reported
an approximately linear increase in fibrin deposition after
a very small lag phase (Fig. 4 B). Yet the fibrin-deposition
kinetics observed in other flow-chamber studies (32,33)
qualitatively agreed with our results (Fig. 4 B). Indeed,
both of these experimental studies (performed at different
venous shear rates) reported a lag in fibrin production1874 Biophysical Journal 110, 1869–1885, April 26, 2016
FIGURE 4 Fibrin deposition is determined by
thrombin generation. (A) Time-dependent maximal
values of the model-predicted spatial distribution of
thrombin concentration. (B) Fibrin deposition pre-
dicted by the model is compared with data from
flow-chamber experiments. The solid line (no sym-
bols) shows the normalized integral of the model-
predicted fibrin concentration calculated over the
entire flow domain. The lines with markers repre-
sent the normalized fibrin levels (determined using
fluorescence-intensity measurements) reported in
different flow-chamber experiments. Data points,
represented by the symbols, were connected with
solid lines to enhance the visual representation of
the displayed trends. To facilitate data comparisons,
the model-generated and experimental data were
independently normalized to their corresponding
maximal values. (C) Time-dependent maximal
values of the model-predicted spatial distribution
of the intrinsic tenase concentration. (D) Time-
dependent maximal values of the model-predicted
spatial distribution of the prothrombinase concen-
tration.
Modeling Thrombus Formation under Flowfollowed by a sharp, nonlinear rise in the fibrin level, as was
predicted by our model. Taken together, these results indi-
cate that some details of thrombus formation kinetics may
differ depending on the experimental setup. Our model
may not reproduce such nuances, but it appears to capture
some of the main experimentally observed trends.
It is generally known that thrombin generation is strongly
influenced by the activity of two main enzyme complexes,
intrinsic tenase (VIIIa:IXa) and prothrombinase (Va:Xa),
formed on platelet surfaces (36,69). To obtain insights into
their roles in shaping thrombin kinetics under flow, we
plotted their time courses (Fig. 4, C and D) and compared
them with that of thrombin (Fig. 4 A). Interestingly, the
prothrombinase kinetics were qualitatively similar to that
of thrombin, whereas the intrinsic tenase kinetics were
different. As could be expected, the prothrombinase kinetics
slightly preceded the thrombin kinetics, reflecting the causal
relationship between prothrombinase activity and thrombin
generation. These results suggest that, under the conditions
of our simulation, thrombin kinetics is determined primarily
by prothrombinase rather than by intrinsic tenase.Platelets, thrombin, and fibrin are characterized
by distinct spatial distributions in the thrombus
Our model reflected the temporal process of platelet accu-
mulation at the thrombogenic surface location (Fig. 5). As
expected, initially there was no detectable platelet deposi-tion (Fig. 5 A). During the first 100 s of the simulation, a
thin layer of platelets was deposited at the thrombogenic
surface (Fig. 5 B). By ~200 s, the platelet deposition had
grown and was blocking ~27% of the flow-chamber height,
with a higher fraction of platelets present near the throm-
bogenic surface (Fig. 5 C). These platelets were activated
predominantly by collagen (~63%) and ADP (~32%),
because substantial amounts of thrombin were seen only
at times exceeding 220 s after thrombus formation initiation
(Fig. 4 A). From 220 s onward, the sharp increase in
thrombin level (Fig. 4 A) began contributing to the accumu-
lation of activated platelets, thereby accelerating the clot’s
growth (Fig. 5, C–E). Throughout the process, platelets
continued to accumulate, occluding the flow chamber
(Fig. 5, B–E). At the end of the simulation (Fig. 5 E), plate-
lets were blocking ~65% of the flow-chamber height.
In our simulation, thrombin and fibrin were more or less
uniformly distributed over the thrombogenic surface, with a
slight increase in concentration at the downstream side
(Fig. 6), which qualitatively agrees with experimental obser-
vations (Fig. 7 C of Colace et al. (31)). At 100 s of the simu-
lation, our model predicted sparse formations of thrombin
spatially distributed on both the upstream and downstream
sides of the thrombogenic surface (Fig. 6 B, left). This
thrombin converted small amounts of fibrinogen to fibrin
(Fig. 6 B, right). By 200 s, our model predicted a slight
increase in thrombin (Fig. 6 C, left) and a resulting increase
in fibrin (Fig. 6 C, right). Around 220 s after thrombusBiophysical Journal 110, 1869–1885, April 26, 2016 1875
FIGURE 5 Spatial distribution of bound platelets deposited at the throm-
bogenic surface. (A–E) The colors represent the fraction of bound platelets
at distinct times in the simulation. This fraction was calculated as the con-
centration of bound platelets divided by the maximal possible number of
platelets in a unit volume (see Supporting Material for details). Only the
flow-chamber channel with the thrombogenic surface is shown. To see
this figure in color, go online.
Govindarajan et al.formation initiation, the rate of thrombin and fibrin gener-
ation increased. Indeed, shortly after 220 s, the thrombin
concentration had exceeded 1 nM and reached the sharp-
rise phase (Fig. 4 A). Consequently, from 220 s onward,
we expected, and witnessed, a dramatic increase in fibrin
levels (Fig. 6, D–E, right).
Our simulation showed that the spatial distribution of
fibrin was concentrated beneath the deposited platelets and
did not extend beyond the distribution of the platelets at
any time during the simulation. The hydraulic resistance im-
parted by 50 nM of fibrin (a concentration achieved within
~300 s in our simulation) exceeded that imparted by the
deposited platelets at their maximal possible density (results1876 Biophysical Journal 110, 1869–1885, April 26, 2016not shown). This suggests that a concentration of 50 nM can
be viewed as the threshold concentration beyond which
fibrin strongly impacts the behavior of the thrombus by
altering its resistance to blood flow. The additional resis-
tance to the growing thrombus imparted by the increasing
local fibrin concentration could further reduce the local
blood-flow velocity inside the thrombus (Fig. S3), thereby
decreasing the momentum imparted by the fluid to adjacent
thrombus particles. This could effectively increase clot sta-
bility, which reflects the ability of the clot to resist the blood
flow and to maintain structural integrity.Occlusion of the flow chamber is dominated by
platelet deposition
At the start of the simulation, blood freely moved through
the flow chamber, because there were no accumulated plate-
lets or fibrin (Fig. 7 A). Equal amounts of blood per unit time
flowed through both channels (with and without a thrombo-
genic surface) of the chamber, converging at the outlet,
where flow velocity was twofold higher than at the inlet,
due to conservation of mass. As thrombus formation pro-
ceeded, regions of high resistance began to form, occluding
the flow. Until 200 s after thrombus formation initiation
(Fig. 7, B and C), resistance imparted to the flow was mostly
due to platelet deposition, because there was no substantial
accumulation of fibrin. Hence, hydraulic resistance due to
platelet deposition appeared sufficient to alter the blood
flow in the flow chamber. Throughout the simulation, the
bottom channel experienced occlusion due to thrombus
growth, and there was a corresponding increase in blood
flow in the upper channel (Fig. 7, B–E).
The increased fibrin deposition over the thrombogenic
surface (Fig. 6, C–E, right) correlated with the increased hy-
draulic resistance at the downstream side of the thrombus
(Fig. 7, D and E, left). This suggests that increasing hydrau-
lic resistance was more strongly driven by fibrin than by the
accumulation of platelets, which showed a noticeably more
uniform distribution along the thrombogenic surface
(Fig. 5). In fact, the model-predicted maximal hydraulic
resistance imparted by fibrin at the end of the simulation
was up to ~30-fold higher than that imparted by platelets.
(By comparison, Colace et al. observed that fibrin increased
thrombus strength by up to 28-fold (31).) Nevertheless, the
area of low axial velocity in the flow through the chamber
(Fig. 7, B–E, right) mimicked the symmetric distribution
of platelets in the thrombus, which extended beyond the
area of fibrin accumulation (Fig. 5, B–E). Because
decreased axial velocity is the main physical indicator of
flow occlusion, this result demonstrates that flow-chamber
occlusion was due mainly to platelet accumulation. This,
in turn, implies that the hydraulic resistance of the upper
portion of the thrombus (due largely to platelets) was suffi-
cient to force the flow to bypass the thrombus area. Yet the
increased hydraulic resistance and fibrin accumulation
FIGURE 6 Spatial distribution of generated
thrombin (left) and deposited fibrin (right) in the
simulation. (A–E) The colors represent the con-
centrations of thrombin and fibrin at distinct times
in the simulation. Only the flow-chamber channel
with the thrombogenic surface is shown. To see
this figure in color, go online.
Modeling Thrombus Formation under Flowsuggest that the lower part of the thrombus would be
more stable (as explained in the previous subsection) than
its upper part.Fibrinogen supplementation impacts the
hydraulic resistance (clot strength) in a nonlinear
fashion
To investigate the effect of fibrinogen supplementation on
thrombus formation, we performed three additional simula-
tions, increasing the fibrinogen level by 16%, 32%, and
48% of the default fibrinogen level (all other simulation con-
ditions were kept constant; see Materials and Methods). Our
model predicted that for all considered fibrinogen levels
(i.e., 100%, 116%, 132%, and 148%), the fibrin concentration
threshold of 50 nM (i.e., the threshold beyond which the hy-
draulic resistance (clot strength) imparted by fibrin exceeds
that imparted by deposited platelets) was reached at ~300 s
in the simulation (results not shown). This result illustrates
that the onset time of the fibrin-generation surge did not
strongly depend on the fibrinogen level. Yet, at the end of
the simulations, we observed a notable difference in the
maximal fibrin level between different fibrinogen supplemen-
tation scenarios (Fig. 8A). This result indicates that during the
later phases of thrombus formation, thrombus strength may
depend significantly on the blood fibrinogen level.
In our simulations, we increased the fibrinogen level in
a linear fashion. However, the corresponding increase in
the maximal hydraulic resistance imparted by fibrin was
strongly nonlinear (Fig. 8 B). The region of maximalresistance was located at the downstream side of the throm-
bogenic surface (~320mmdownstream from the inlet), where
fibrin concentrationwas higher (indicatedwith awhite line in
Fig. 8 C). Moreover, although the increase in the fibrinogen
level did not exceed 50%, the maximal hydraulic resistance
increased by ~2.7-fold. By comparison, the fibrinogen-
dependent increase in the fibrin level was smaller and did
not exceed ~1.7-fold (Fig. 8 A). Therefore, the large fibrin-
ogen-dependent change in hydraulic resistance was due pri-
marily to the nonlinearity of the expression describing the
fibrin level’s effect on hydraulic resistance (Eq. 8).
Based on these results, we anticipated a fibrinogen-
dependent increase in the hydraulic resistance in the area
of fibrin accumulation within the thrombus, i.e., in its lower
part adjacent to the thrombogenic surface. A comparison
of the thrombus shape for 100% and 148% fibrinogen
confirmed this expectation (Fig. 8 C, red area). Yet the over-
all area of heightened hydraulic resistance imparted by
fibrin remained nearly unchanged (Fig. 8 C). This result
suggests that fibrinogen supplementation did not impact
the shape or size of the thrombus, resulting in an unchanged
total flow profile (Fig. S1). This finding is consistent with
our simulation for the default fibrinogen level, which sug-
gested that the thrombus shape and size were determined
primarily by platelet deposition rather than by fibrin accu-
mulation (Figs. 5 and 7). Interestingly, a recent modeling
study, which used a model with explicit representation of
platelets as mechanical particles, suggested that initial
fibrinogen concentration can impact the number of depos-
ited platelets and, therefore, clot size (70). These resultsBiophysical Journal 110, 1869–1885, April 26, 2016 1877
FIGURE 7 Platelet and fibrin deposition occludes the flow through the bottom channel of the flow chamber. (A–E) The colors represent the hydraulic
resistance (left) and axial flow velocity (right) in the flow chamber at distinct times in the simulation. To see this figure in color, go online.
Govindarajan et al.appear to complement our findings, because they pertain to
the case of fibrinogen deficiency, whereas we consider the
case of fibrinogen supplementation (i.e., R100% fibrin-
ogen). Taken together, these findings may suggest a satura-
tion effect: severely decreased fibrinogen levels may result
in a reduction in thrombus size, whereas a moderate increase
in the fibrinogen level beyond the typical normal value may
only marginally impact thrombus formation and the result-
ing blood-flow pattern.
We investigated the effect of fibrinogen supplementation on
blood flow within the thrombus by analyzing the dependence
of the flow’s axial velocity on the vertical distance (indicated
by the white line in Fig. 8 C where fibrin concentration was
higher) from the thrombogenic surface. For all considered
fibrinogen levels, this dependency had a similar sigmoidal
shape (Fig. 8D). As expected, at all distances from the throm-
bogenic surface, axial flow velocity monotonically decreased
upon fibrinogen supplementation. The fibrinogen-dependent
decrease in the flow velocity was distance dependent,
achieving up to ~1.3-foldmagnitude (at 8 mm from the throm-
bogenic surface). Thus, fibrinogen supplementation can
significantly affect blood flow through the fibrin-rich lower1878 Biophysical Journal 110, 1869–1885, April 26, 2016portion of the thrombus.Notably, for all consideredfibrinogen
levels, the axial velocity dependence on the distance from the
thrombogenic surface converged to the sameplateau for larger
distance values (>13 mm from the thrombogenic surface)
(Fig. 8 D). This result suggests that the effect of fibrinogen
supplementation on the blood-flow velocity did not extend
beyond a certain height, which was nearly the same for all
the fibrinogen supplementation levels. That height can be in-
terpreted as the boundary of the thrombus-occupied area
where relatively less fibrin was present, but which was rich
in platelets. This is consistent with our finding that the shape
and size of the area of reduced axial velocity (i.e., the outer
shape and size of the thrombus) was generally determined
by the area of platelet deposition, which extended beyond
the area of fibrin deposition.Fibrinogen and PCC supplementation increase
the thrombus hydraulic resistance during blood
dilution
In our simulations, as expected (63), the level of generated
thrombin was strongly reduced (by ~3.1-fold) by dilution
FIGURE 8 The model predicted an increase in
hydraulic resistance upon fibrinogen supplementa-
tion. (A) Fibrin generation for various fibrinogen
supplementation levels (16%, 32%, and 48%
beyond the normal level of 5.4 mM). (B) Maximal
hydraulic resistance imparted by the generated
fibrin in the flow chamber at 430 s. The initial
data point (at 0% supplemented fibrinogen level)
represents the maximal resistance imparted at the
default fibrinogen level. (C) Spatial distribution of
hydraulic resistance imparted by normal fibrinogen
level and by 48% fibrinogen supplementation at
430 s. (D) Flow axial velocity plotted against the
vertical distance from the thrombogenic surface
at the region of maximal hydraulic resistance (indi-
cated by thewhite line in C) within the clot at 430 s.
Each axial velocity curve corresponds to one of the
considered fibrinogen levels. To see this figure in
color, go online.
Modeling Thrombus Formation under Flowand unaffected by fibrinogen supplementation (Fig. 9 A).
Interestingly, an in vitro experimental study conducted
by Bolliger et al. reported that thrombin is reduced by
~2.3-fold under plasma dilution (71). In our model simula-
tions, the fibrin level was also significantly reduced by dilu-
tion (at 430 s, by at least an order of magnitude), and
fibrinogen supplementation had a strongly nonlinear effect
on fibrin generation (Fig. 9 B). Indeed, at 430 s, the fibrin
level for 16% supplemented fibrinogen was ~1.5-fold higher
than that in unsupplemented blood, but only marginally
lower than in the cases of 32% and 48% supplemented
fibrinogen. Moreover, in the latter case, the total fibrinogen
level was 88% of its normal undiluted value, but the corre-
sponding level of fibrin at 430 s was ~5-fold lower than
normal (Fig. 9 B). This could be attributed to the fact that
the rate of fibrin production is proportional to the product
of the thrombin and fibrinogen concentrations (Eq. S29),
and the dilution-reduced thrombin concentration did not in-
crease under fibrinogen supplementation. This is consistent
with the conclusion made by Bolliger et al. that fibrinogen
supplementation by ~100% of the normal value is required
for optimized clot formation (71). Our results on fibrinogen
supplementation in diluted blood are also consistent with
our previously obtained simulation results showing that
fibrinogen supplementation alone does not fully restore
the normal fibrin kinetics (72). At the same time, additional
supplementation with a PCC increased thrombin concentra-
tion by ~2.75-fold, thus producing a thrombin level that was
~85% of its normal value (Fig. 9 A). This extra thrombinincreased the generated fibrin level, which at 430 s was
~80% of its normal value (Fig. 9 B).
To assess the functional consequences of dilution/sup-
plementation-induced differences in the fibrin level, we
compared the hydraulic resistance inside the thrombus for
unsupplemented diluted blood with that for fibrinogen-
supplemented and PCCþfibrinogen-supplemented diluted
blood. The increase in fibrin generation due to PCCþfibri-
nogen supplementation increased the hydraulic resistance
by ~8-fold (Fig. 9 C). Furthermore, we analyzed the axial
flow velocity inside the thrombus for diluted and supple-
mented blood (Fig. 9 D). As expected, dilution increased
the flow velocity, reflecting a relatively weaker ability of
the clot to resist blood flow. The dependence of the axial
velocity on the amount of supplemented fibrinogen was
strongly nonlinear. The blood-flow velocity in the thrombus
region for all fibrinogen supplementation levels was consid-
erably lower than that in unsupplemented diluted blood.
Although this implies that fibrinogen supplementation
can improve hemostasis (Fig. 9 D), even the 48% fibrin-
ogen supplementation could not (approximately) restore
the normal (i.e., predilution) flow-velocity value. At the
same time, PCC and 48% fibrinogen supplementation nearly
restored the interthrombus blood velocity to its normal value
(Fig. 9 D). Taken together, our results suggest that under
blood dilution conditions, normal clot formation cannot
be restored by fibrinogen supplementation alone, and simul-
taneous enhancement of thrombin generation is prefer-
able. This can be achieved using additional clotting-factorBiophysical Journal 110, 1869–1885, April 26, 2016 1879
FIGURE 9 Effects of blood dilution, fibrinogen
supplementation, and PCC supplementation on
thrombus development. (A) Thrombin generation
for various fibrinogen supplementation levels
(16%, 32%, and 48% of 5.4 mM beyond the diluted
level of 2.16 mM and PCC supplementation). Note
that the thrombin level did not change during
fibrinogen supplementation hence the overlap be-
tween the curves for diluted blood and those for
fibrinogen supplementation. (B) Fibrin generation
for various fibrinogen supplementation levels and
48%þPCC fibrin supplementation. (C) Maximal
hydraulic resistance imparted by generated fibrin
for different fibrinogen supplementation levels
and for 48%þPCC fibrin supplementation at 430
s. (D) Flow axial velocity plotted against the verti-
cal distance from the thrombogenic surface at the
region of maximal hydraulic resistance within the
clot at 430 s. Each axial velocity curve corresponds
to one of the considered fibrinogen supplementa-
tion levels. To see this figure in color, go online.
Govindarajan et al.supplements, such as a PCC. This conclusion is consistent
with our previously obtained in vitro blood coagulation
simulation results and implies that fibrinogen should be
used in combination with other clotting factors to improve
clot formation in coagulopathy (65,72).DISCUSSION
Normal functioning of the blood coagulation system is
essential for human survival, which continues to motivate
attempts to clarify the mechanistic details of blood clotting.
Despite extensive research, the time-dependent spatial orga-
nization, and its connection with the functional properties,
of a growing thrombus have not been fully understood.
Yet such understanding may be critical for our ability to pre-
dict and control thrombus growth, including its modulation
by therapeutic interventions. Here, we developed a compu-
tational model of thrombus formation in a flow chamber
(Figs. 3 and 4) based on the framework previously devel-
oped by Leiderman and Fogelson (22). We extended that
framework by 1) including explicit representations of fibrin
generation; 2) implementing an enhanced platelet and
biochemical species diffusivity model with a varying hemat-
ocrit profile; 3) implementing a field potential function in
the mobile-platelets-governing equation to account for
platelet margination due to the presence of red blood cells;
4) implementing a shear-dependent platelet-adhesion rate
constant to represent the effect of shear rate on platelet
adhesion; 5) adding specific binding sites for zymogens1880 Biophysical Journal 110, 1869–1885, April 26, 2016and enzymes on platelet surfaces, with binding-site numbers
obtained from the literature and factor X sharing the binding
sites with prothrombin; 6) implementing the activation of
prothrombin to thrombin in plasma by the action of factor
Xa; and 7) reflecting the contributions of fibrin to the me-
chanical properties of the growing thrombus. We applied
the model to investigate the accumulation of the thrombus’
main enzymatic component (i.e., thrombin) and structural
components (i.e., platelets and fibrin). Our model predicted
distinct spatial distribution patterns for platelets, thrombin,
and fibrin (Figs. 5 and 6) and identified platelet accumula-
tion as the primary driver of blood-flow occlusion by a
growing thrombus (Figs. 5 and 7). Moreover, we used the
model to establish the nonlinear dependencies of thrombus
characteristics on the amount of supplemented fibrinogen
(Fig. 8) and to investigate the effect of fibrinogen and
PCC supplementation on thrombus formation in diluted
blood (Fig. 9), which has been shown to potentially
improve hemostasis in trauma patients with severe bleeding
(73,74).
Our model semiquantitatively reproduced the dynamics
of platelet deposition and the area of platelet deposition
measured in experiments. Similarly to the thrombin dy-
namics predicted by our model, rapid thrombin accumula-
tion after an initial delay is a salient feature of thrombin
generation assays performed in vitro in the absence of
flow (i.e., ‘‘static’’ assays) (8,36,75). Likewise, typical ki-
netic curves of fibrin accumulation in static assays are char-
acterized by a delay followed by a rapid onset of fibrin
Modeling Thrombus Formation under Flowgeneration (8,72). Thrombin generation delay corresponds
to its initiation phase, which is due to well-studied thrombin
generation biochemistry (36). The time when the thrombin
concentration reaches 2–10 nM is known as clotting time
and defines the time of onset of fibrin generation (36,75).
Thus, delays followed by rapid bursts in thrombin and fibrin
accumulation are determined by the basic biochemistry of
these processes and therefore should generally be expected.
In accord with this expectation, the original LF computa-
tional model, applied to thrombus formation in a flow cham-
ber, predicted a pronounced delay followed by a rapid
increase in the thrombin concentration (32). Our predictions
for thrombin and fibrin generation are consistent with this
behavior, as are the flow-chamber measurements by Ona-
soga-Jarvis et al. (Fig. 4 B). The somewhat unexpected early
accumulation of fibrin in the flow chamber used by Colace
et al. (Fig. 4 B) suggests some portions of thrombin, present
early, as a possible cause. We performed supplemental sim-
ulations with an added amount of thrombin specified at the
inlet (all other simulation conditions remained unchanged;
see Materials and Methods). The simulations showed that
the presence of thrombin in plasma (which may result
from accidental activation of the coagulation system during
blood sample collection) could indeed result in fibrin accu-
mulation kinetics similar to that observed in the experiment
(Fig. S2). Direct thrombin measurements in the experi-
mental system would further clarify the basis for early fibrin
accumulation.
The studies of spatial distribution of platelets, thrombin,
and fibrin were initiated ~15 years ago in mouse models
of blood coagulation using intravital microscopy (1,76).
However, due to the differences between mouse and human
biochemistry and physiology, such studies provide only par-
tial answers about blood coagulation in the human and
should be supplemented by other approaches. Our model
of blood coagulation relies on mechanisms and numerical
parameter values expected to correspond to the blood coag-
ulation process in humans, and the predicted results can be
compared with both flow-chamber experiments and intra-
vital microscopy data.
Consistent with in vivo studies, platelet accumulation and
the spreading of fibrin through the thrombus in our simula-
tions occurred as concurrent processes, challenging the
traditional paradigm of ‘‘platelet plug’’ formation and fibrin
accumulation as distinct processes occurring one after the
other (1). Furthermore, in accord with both intravital micro-
scopy data and the flow-chamber experiments of Colace
et al. (31), the area of platelet accumulation included and ex-
ceeded that of fibrin accumulation. Moreover, consistent
with intravital microscopy data, our model predicted the
presence of thrombin throughout the thrombus, not just at
the thrombus-blood interface (1). Interestingly, the flow-
chamber measurements of Colace et al. (31) demonstrate
that fibrin accumulates preferentially at the downstream
part of the thrombogenic surface and does not extendbeyond the platelet accumulation area, which is captured
in our modeling predictions for both fibrin and thrombin
accumulation. However, intravital microscopy data suggest
that fibrin accumulates predominantly at the upstream side
of the growing platelet thrombus (76), or that the distribu-
tion of fibrin is symmetrical about the thrombus center
line (77). A plausible reason for these discrepancies is the
spatial structure of the experimentally induced lesion that
activates thrombus formation in vivo, but the real reason
for the discrepancies may lie deeper.
A unique advantage of computational modeling of
thrombus formation lies in the possibility of simultaneously
predicting both thrombus structure/composition and its
physical properties, such as hydraulic resistance and flow
velocity inside the thrombus or in its vicinity. Currently
used experimental approaches cannot achieve simultaneous
measurement of these physical properties. This is why our
predictions regarding the correspondence between thrombus
structure and blood-flow mechanics cannot be validated
by direct comparison with experimental data. However,
although it is not preferable, our predictions can be assessed
using comparisons with other computational modeling
studies. Indeed, computations with the original LF model
(which did not represent fibrin accumulation) showed that
deposited platelets could effectively slow down and divert
the blood flow in their vicinity (22). Interestingly, in that
computation, the up- and downstream slopes of the area of
reduced flux velocity near the thrombus were more gradual
than the slopes of the area of platelet accumulation, which is
consistent with our computations. A modeling study that
involved a representation of platelets as discrete particles
showed that even loose platelet aggregates can noticeably
decrease the fluid flow through the area (18). Because the
platelet deposition area typically exceeds that of fibrin
deposition, these results suggest that the outer boundaries
of the thrombus would be defined by the spatial platelet dis-
tribution. This pattern was consistently demonstrated in our
simulations.
A computational modeling approach offers the possibility
of delineating the individual contributions of distinct model
features, representing different aspects of the fluid dy-
namics, chemistry, and biology of blood coagulation. This
can be illustrated by a brief comparison of the current
version of our model (considered in this article) and earlier
model versions. The current version of our model incorpo-
rates a number of added features (such as platelet binding
sites with protein-specific binding constants, prothrombin
activation in plasma, and ADP-dependent platelet activa-
tion), some (or all) of which were absent in earlier model
versions. For a number of model versions that incorporate
different subsets of these features, we analyzed the deposi-
tion of platelets and the generation of thrombin and fibrin, as
well as the flow axial velocity inside the growing thrombus.
We found that the most recent model extensions (namely,
the incorporation of initially reversible platelet capture,Biophysical Journal 110, 1869–1885, April 26, 2016 1881
Govindarajan et al.the use of a shear-dependent platelet adhesion rate constant,
explicit modeling of platelet margination, and the use of
local shear rate in Eq. 2) resulted in the following two qual-
itative changes in model behavior. First, the platelet deposi-
tion height profile shows ‘‘bumps’’ on the upstream and
downstream sides (Fig. 3 B) that were absent in our simula-
tions with earlier model versions. Second, the spatial growth
of thrombin and fibrin is characterized by a more evenly
distributed profile (Fig. 6), compared to the earlier model
versions during the first 430 s of thrombus growth. The pres-
ence or absence of other above-mentioned model features
did not change the model properties and resulted only in
moderate (up to ~30%) quantitative changes in the consid-
ered outputs. Yet it is conceivable that the differences
caused by the added model features could be larger for other
(e.g., arterial) flow conditions and other domains (i.e., flow-
chamber or blood-vessel geometries).
Our modeling prediction that the timing of the onset of
fibrin generation is insensitive to fibrinogen supplementa-
tion, whereas the final fibrin level is not, is in accord with
experimental and modeling results for static fibrin genera-
tion assays (12,72). The fibrinogen-modulated increase in
the amount of deposited fibrin and the resulting increase
in hydraulic resistance inside the thrombus were to be ex-
pected. However, the interpretation of the clinical data on
fibrinogen-dependent improvements in blood clotting
(5,10,11) is less straightforward, given that the function of
a thrombus to reduce and divert blood flow is due primarily
to the deposited platelets rather than to fibrin. The underly-
ing mechanism for the improvements may be the destruc-
tion of the outer, fibrin-free layer of the thrombus by the
oncoming blood flow, which may slow down the overall
speed of thrombus growth. When fibrin generation is stimu-
lated, increased fibrin deposition will stabilize a larger part
of the clot; integrated over many clots, this effect may ac-
count for the clinical benefits of fibrinogen supplementation.
Our analysis of the blood-flow occlusion due to thrombus
formation has implications for the problem of thrombus-
size control. Indeed, our computations suggest that, as clot
growth proceeds, the flow velocity above the thrombus re-
gion increases (due to the conservation of mass for the total
blood flow) (Fig. 7). This implies that the increased convec-
tive forces will result in more platelets being carried away
from the side of the clot facing the lumen. According to
our modeling results, the size of the thrombus is determined
primarily by platelet deposition. Therefore, platelet ‘‘wash-
off’’ is expected to limit the growth rate and the size of the
clot. This hypothesis is supported by the computational
study of Pivkin et al. (with explicit representation of plate-
lets as individual particles), who observed that thrombus
growth rate depends on blood-flow velocity and that after
an initial increase in clot size, portions of thrombus can
break off and be carried away as emboli (25). In contrast,
other computational modeling studies propose alternative
mechanisms of clot-size control. One such mechanism is1882 Biophysical Journal 110, 1869–1885, April 26, 2016the hindered transport of coagulation proteins into the
thrombus in regions of high platelet density, which was sug-
gested in a study based on the use of the LF model (22,69).
Moreover, some studies have suggested that fibrin does not
have a large impact on protein diffusive transport (78), and
others have reported that fibrin decreases the permeability
of the thrombus (79). Our analysis suggests that because
the local flow velocity in the clot is reduced due to both
platelets and fibrin, increased density of either one can
slow down the transport of coagulation proteins into the
thrombus. In fact, our study shows that fibrin-rich thrombus
regions impart a larger hydraulic resistance (inverse of
permeability) compared to regions with lower fibrin concen-
trations (Figs. 6 and 7). This results in a greater reduction of
the local flow velocity in fibrin-rich regions of the thrombus
(Fig. S3) and thus seems to support the hypothesis that fibrin
may alter the flow, and hence the transport, of proteins due
to a decreased permeability (79,80).
Another possible mechanism of clot-size control is the
formation of a ‘‘fibrin cap’’ on the surface of the thrombus,
which impedes thrombin diffusion, thereby restricting the
activation of additional platelets and the formation of addi-
tional fibrin molecules (81). This is consistent with experi-
mental results from the same group (78). Because our
study suggests that the domain of fibrin accumulation does
not exceed that of platelet accumulation (which is in accord
with computational (70) and experimental (31,82) results
by other groups), it does not provide a strong support for
the fibrin-cap hypothesis under the considered simulation
conditions. A likely contributor to thrombus-size control is
the naturally occurring process of fibrinolysis, which may
take place on the same timescale as thrombus formation
(72). Further computational and experimental studies are
warranted to assess the possibility of simultaneous contribu-
tions of all these mechanisms to thrombus-size control, as
well as to identify predominant mechanisms and their
dependence on clot-formation conditions.
The modeling study reported in this article has a number
of limitations. First, this is a computational study, and much
remains to be done to ensure proper experimental validation
of all our computational predictions. Comparisons with
experimental data reported here show that the model can
reproduce several salient features of clot formation under
flow (Figs. 3 and 4). Second, this work represents thrombus
formation in a flow chamber, which only partially represents
blood coagulation in vivo. Yet flow-chamber experiments
provide the control and flexibility that cannot be achieved
by other experimental or observational techniques, and
they define an important step toward understanding how
blood clots in the body. Third, our model gives a simplified
representation of the thrombus-formation process. Indeed,
our 2D model contains a reduced biochemical model of
thrombin generation, does not account for fibrin polymeri-
zation or fibrinolysis, and does not explicitly represent
platelets and red blood cells as mechanical bodies flowing
Modeling Thrombus Formation under Flowwith the blood. As a result, our model does not explicitly
represent platelet-fibrin interactions and the dependence of
platelet-platelet interactions on fibrin levels. Nevertheless,
computational-fluid-dynamics-based approaches similar
to ours can generate modeling predictions consistent with
experimental data and yield insights useful for the un-
derstanding of thrombus formation as a kinetic process.
This is because they provide a reasonable compromise
between the intention to accurately reflect clot formation
and the extreme mechanistic complexity of this process
(17,20,22,24,26–28,34).
This work investigates thrombus formation as a process
developing (primarily) in two dimensions. However, the
representation of the physical and chemical processes in
the model can be immediately extended to three dimen-
sions and applied to model blood coagulation in realistic
blood vessel geometries and flow conditions, including
the presence of hemorrhage from a breached vessel.
Our work thus defines a direction for future investigations
aimed at generating testable hypotheses about thrombus
formation in vivo. Furthermore, such an approach can
be extended to provide strategies for predictive analysis
of the effects of pharmacologic agents on blood clotting
in the human body. Improvements in the accuracy of
our model’s components will allow us to increase and
test our understanding of blood coagulation as a natural
phenomenon.SUPPORTING MATERIAL
Model equations, three figures, and nine tables are available at http://www.
biophysj.org/biophysj/supplemental/S0006-3495(16)30059-5.
AUTHOR CONTRIBUTIONS
V.G., V.R., J.R., and A.Y.M designed the research. V.G., V.R., and A.Y.M
performed the research. V.G., V.R., J.R., and A.Y.M analyzed the data.
V.G., J.R., and A.Y.M wrote the article.ACKNOWLEDGMENTS
The authors are grateful to Drs. Scott Diamond, Karin Leiderman, and
Konstantinos Vogiatzis for valuable discussions, and to four anonymous re-
viewers whose comments and suggestions helped the authors to improve the
article. The opinions and assertions contained herein are the private views
of the authors and are not to be construed as official or as reflecting the
views of the U.S. Army or of the U.S. Department of Defense. This article
has been approved for public release with unlimited distribution.
This work was supported by the U.S. Army Network Science Initiative,
U.S. Army Medical Research and Materiel Command, Fort Detrick, MD.
High-performance computing resources were made available by the U.S.
Department of Defense High Performance Computing Modernization
Program.SUPPORTING CITATIONS
References (83–98) appear in the Supporting Material.REFERENCES
1. Furie, B., and B. C. Furie. 2007. In vivo thrombus formation.
J. Thromb. Haemost. 5 (Suppl 1):12–17.
2. Monroe, D. M., and M. Hoffman. 2006. What does it take to make the
perfect clot? Arterioscler. Thromb. Vasc. Biol. 26:41–48.
3. Spronk, H. M., J. W. Govers-Riemslag, and H. ten Cate. 2003. The
blood coagulation system as a molecular machine. BioEssays.
25:1220–1228.
4. Undas, A., and R. A. Arie¨ns. 2011. Fibrin clot structure and function:
a role in the pathophysiology of arterial and venous thromboembolic
diseases. Arterioscler. Thromb. Vasc. Biol. 31:e88–e99.
5. Levy, J. H., F. Szlam,., R. M. Sniecienski. 2012. Fibrinogen and he-
mostasis: a primary hemostatic target for the management of acquired
bleeding. Anesth. Analg. 114:261–274.
6. Machlus, K. R., M. M. Aleman, and A. S. Wolberg. 2011. Update on
venous thromboembolism: risk factors, mechanisms, and treatments.
Arterioscler. Thromb. Vasc. Biol. 31:476–478.
7. Nesbitt, W. S., E. Westein, ., S. P. Jackson. 2009. A shear gradient-
dependent platelet aggregation mechanism drives thrombus formation.
Nat. Med. 15:665–673.
8. Wolberg, A. S. 2007. Thrombin generation and fibrin clot structure.
Blood Rev. 21:131–142.
9. Mosesson, M. W. 2005. Fibrinogen and fibrin structure and functions.
J. Thromb. Haemost. 3:1894–1904.
10. Dane´s, A. F., L. G. Cuenca,., J. B. Ronsano. 2008. Efficacy and toler-
ability of human fibrinogen concentrate administration to patients with
acquired fibrinogen deficiency and active or in high-risk severe
bleeding. Vox Sang. 94:221–226.
11. Karlsson, M., L. Ternstro¨m,., A. Jeppsson. 2009. Prophylactic fibrin-
ogen infusion reduces bleeding after coronary artery bypass surgery. A
prospective randomised pilot study. Thromb. Haemost. 102:137–144.
12. Machlus, K. R., J. C. Cardenas,., A. S. Wolberg. 2011. Causal rela-
tionship between hyperfibrinogenemia, thrombosis, and resistance to
thrombolysis in mice. Blood. 117:4953–4963.
13. Brown, A. E., R. I. Litvinov, ., J. W. Weisel. 2009. Multiscale me-
chanics of fibrin polymer: gel stretching with protein unfolding and
loss of water. Science. 325:741–744.
14. Ryan, E. A., L. F. Mockros,., L. Lorand. 1999. Structural origins of
fibrin clot rheology. Biophys. J. 77:2813–2826.
15. Diamond, S. L. 2013. Systems biology of coagulation. J. Thromb.
Haemost. 11 (Suppl 1):224–232.
16. Xu, Z., M. Kamocka, ., E. D. Rosen. 2011. Computational ap-
proaches to studying thrombus development. Arterioscler. Thromb.
Vasc. Biol. 31:500–505.
17. Anand, M., K. Rajagopal, and K. R. Rajagopal. 2005. A model for the
formation and lysis of blood clots. Pathophysiol. Haemost. Thromb.
34:109–120.
18. Flamm, M. H., T. V. Colace, ., S. L. Diamond. 2012. Multiscale
prediction of patient-specific platelet function under flow. Blood.
120:190–198.
19. Fogelson, A. L., and N. Tania. 2005. Coagulation under flow: the
influence of flow-mediated transport on the initiation and inhibition
of coagulation. Pathophysiol. Haemost. Thromb. 34:91–108.
20. Jordan, S. W., and E. L. Chaikof. 2011. Simulated surface-induced
thrombin generation in a flow field. Biophys. J. 101:276–286.
21. Kuharsky, A. L., and A. L. Fogelson. 2001. Surface-mediated control
of blood coagulation: the role of binding site densities and platelet
deposition. Biophys. J. 80:1050–1074.
22. Leiderman, K., and A. L. Fogelson. 2011. Grow with the flow: a
spatial-temporal model of platelet deposition and blood coagulation
under flow. Math. Med. Biol. 28:47–84.
23. Mori, D., K. Yano, ., T. Yamaguchi. 2008. Simulation of platelet
adhesion and aggregation regulated by fibrinogen and von Willebrand
factor. Thromb. Haemost. 99:108–115.Biophysical Journal 110, 1869–1885, April 26, 2016 1883
Govindarajan et al.24. Panteleev, M. A., M. V. Ovanesov, ., F. I. Ataullakhanov. 2006.
Spatial propagation and localization of blood coagulation are regulated
by intrinsic and protein C pathways, respectively. Biophys. J. 90:1489–
1500.
25. Pivkin, I. V., P. D. Richardson, and G. Karniadakis. 2006. Blood flow
velocity effects and role of activation delay time on growth and form
of platelet thrombi. Proc. Natl. Acad. Sci. USA. 103:17164–17169.
26. Rugonyi, S., E. Tucker,., S. Hanson. 2010. Transport-reaction model
of mural thrombogenesis: comparisons of mathematical model predic-
tions and results from baboon models. Ann. Biomed. Eng. 38:2660–
2675.
27. Sorensen, E. N., G. W. Burgreen,., J. F. Antaki. 1999. Computational
simulation of platelet deposition and activation: II. Results for Pois-
euille flow over collagen. Ann. Biomed. Eng. 27:449–458.
28. Sorensen, E. N., G. W. Burgreen,., J. F. Antaki. 1999. Computational
simulation of platelet deposition and activation: I. Model development
and properties. Ann. Biomed. Eng. 27:436–448.
29. Tosenberger, A., F. Ataullakhanov,., V. Volpert. 2013. Modelling of
thrombus growth in flow with a DPD-PDE method. J. Theor. Biol.
337:30–41.
30. Xu, Z., J. Lioi, ., M. Alber. 2010. A multiscale model of venous
thrombus formation with surface-mediated control of blood coagula-
tion cascade. Biophys. J. 98:1723–1732.
31. Colace, T. V., R. W. Muthard, and S. L. Diamond. 2012. Thrombus
growth and embolism on tissue factor-bearing collagen surfaces under
flow: role of thrombin with and without fibrin. Arterioscler. Thromb.
Vasc. Biol. 32:1466–1476.
32. Onasoga-Jarvis, A. A., K. Leiderman, ., K. B. Neeves. 2013. The
effect of factor VIII deficiencies and replacement and bypass therapies
on thrombus formation under venous flow conditions in microfluidic
and computational models. PLoS One. 8:e78732.
33. Onasoga-Jarvis, A. A., T. J. Puls, ., K. B. Neeves. 2014. Thrombin
generation and fibrin formation under flow on biomimetic tissue fac-
tor-rich surfaces. J. Thromb. Haemost. 12:373–382.
34. Neeves, K. B., D. A. Illing, and S. L. Diamond. 2010. Thrombin flux
and wall shear rate regulate fibrin fiber deposition state during poly-
merization under flow. Biophys. J. 98:1344–1352.
35. Krishnaswamy, S. 2013. The transition of prothrombin to thrombin.
J. Thromb. Haemost. 11 (Suppl 1):265–276.
36. Hockin, M. F., K. C. Jones,., K. G. Mann. 2002. A model for the stoi-
chiometric regulation of blood coagulation. J. Biol. Chem. 277:18322–
18333.
37. Papadopoulos, K. P., M. Gavaises, and C. Atkin. 2014. A simplified
mathematical model for thrombin generation. Med. Eng. Phys.
36:196–204.
38. Carroll, G. T., P. D. Devereux, ., M. T. Walsh. 2010. Experimental
validation of convection-diffusion discretisation scheme employed
for computational modelling of biological mass transport. Biomed.
Eng. Online. 9:34.
39. Wootton, D. M., and D. N. Ku. 1999. Fluid mechanics of vascular sys-
tems, diseases, and thrombosis. Annu. Rev. Biomed. Eng. 1:299–329.
40. Skotheim, J. M., and T. W. Secomb. 2007. Red blood cells and other
nonspherical capsules in shear flow: oscillatory dynamics and the
tank-treading-to-tumbling transition. Phys. Rev. Lett. 98:078301.
41. Zydney, A. L., and C. K. Colton. 1988. Augmented solute transport in
the shear flow of a concentrated suspension. Physicochem. Hydrodyn.
10:77–96.
42. Hund, S. J., and J. F. Antaki. 2009. An extended convection diffusion
model for red blood cell-enhanced transport of thrombocytes and leu-
kocytes. Phys. Med. Biol. 54:6415–6435.
43. Bark, D. L., Jr., and D. N. Ku. 2013. Platelet transport rates and binding
kinetics at high shear over a thrombus. Biophys. J. 105:502–511.
44. Crowl, L., and A. L. Fogelson. 2011. Analysis of mechanisms for
platelet near-wall excess under arterial blood flow conditions.
J. Fluid Mech. 676:348–375.1884 Biophysical Journal 110, 1869–1885, April 26, 201645. Eckstein, E. C., and F. Belgacem. 1991. Model of platelet transport in
flowing blood with drift and diffusion terms. Biophys. J. 60:53–69.
46. Tokarev, A. A., A. A. Butylin, ., F. I. Ataullakhanov. 2011. Finite
platelet size could be responsible for platelet margination effect.
Biophys. J. 101:1835–1843.
47. Buchanan, J. R., Jr., and C. Kleinstreuer. 1998. Simulation of particle-
hemodynamics in a partially occluded artery segment with implications
to the initiation of microemboli and secondary stenoses. J. Biomech.
Eng. 120:446–454.
48. Kumar, A., and M. D. Graham. 2012. Mechanism of margination in
confined flows of blood and other multicomponent suspensions.
Phys. Rev. Lett. 109:108102.
49. Kumar, A., R. G. H. Rivera, and M. D. Graham. 2014. Flow-induced
segregation in confined multicomponent suspensions: effects of parti-
cle size and rigidity. J. Fluid Mech. 738:423–462.
50. Starov, V. M., and V. G. Zhdanov. 2001. Effective viscosity and perme-
ability of porous media. Colloids Surf. A Physicochem. Eng. Asp.
192:363–375.
51. Issa, R. I., A. D. Gosman, and A. P. Watkins. 1986. The computation of
compressible and incompressible recirculating flows by a non-iterative
implicit scheme. J. Comput. Phys. 62:66–82.
52. ANSYS. 2012. FLUENT Manual for ANSYS Release Version 14.5;
ANSYS, Canonsburg, PA.
53. Patankar, S. V. 1980. Numerical Heat Transfer and Fluid Flow: Compu-
tational Methods in Mechanics and Thermal Science. CRC Press, New
York.
54. Barrett, R., M. Berry, ., H. Van der Vorst. 1994. Templates for the
Solution of Linear Systems: Building Blocks for Iterative Methods.
SIAM, Philadelphia, PA.
55. Mattern, K. J., and W. M. Deen. 2008. ‘‘Mixing rules’’ for estimating
the hydraulic permeability of fiber mixtures. AIChE J. 54:32–41.
56. Wufsus, A. R., N. E. Macera, and K. B. Neeves. 2013. The hydraulic
permeability of blood clots as a function of fibrin and platelet density.
Biophys. J. 104:1812–1823.
57. Adolph, R., D. A. Vorp,., S. C. Watkins. 1997. Cellular content and
permeability of intraluminal thrombus in abdominal aortic aneurysm.
J. Vasc. Surg. 25:916–926.
58. Weisel, J. W. 2004. The mechanical properties of fibrin for basic scien-
tists and clinicians. Biophys. Chem. 112:267–276.
59. Davies, C. N. 1950. The separation of airborne dust and particles. Arh.
Hig. Rada. 1:393–427.
60. Blomba¨ck, B., K. Carlsson,., N. A˚slund. 1989. Native fibrin gel net-
works observed by 3D microscopy, permeation and turbidity. Biochim.
Biophys. Acta. 997:96–110.
61. Diamond, S. L., and S. Anand. 1993. Inner clot diffusion and perme-
ation during fibrinolysis. Biophys. J. 65:2622–2643.
62. Wootton, D. M., A. S. Popel, and B. R. Alevriadou. 2002. An experi-
mental and theoretical study on the dissolution of mural fibrin clots
by tissue-type plasminogen activator. Biotechnol. Bioeng. 77:405–419.
63. Mitrophanov, A. Y., F. R. Rosendaal, and J. Reifman. 2012. Computa-
tional analysis of intersubject variability and thrombin generation in
dilutional coagulopathy. Transfusion. 52:2475–2486.
64. Dickneite, G., B. Doerr, and F. Kaspereit. 2008. Characterization of the
coagulation deficit in porcine dilutional coagulopathy and substitution
with a prothrombin complex concentrate. Anesth. Analg. 106:1070–
1077.
65. Mitrophanov, A. Y., F. R. Rosendaal, and J. Reifman. 2012. Therapeu-
tic correction of thrombin generation in dilution-induced coagulop-
athy: computational analysis based on a data set of healthy subjects.
J. Trauma Acute Care Surg. 73 (2, Suppl 1):S95–S102.
66. Tanaka, K. A., M. Mazzeffi, and M. Durila. 2014. Role of prothrombin
complex concentrate in perioperative coagulation therapy. J. Intensive
Care. 2:60.
67. Maloney, S. F., L. F. Brass, and S. L. Diamond. 2010. P2Y12 or
P2Y1 inhibitors reduce platelet deposition in a microfluidic model of
Modeling Thrombus Formation under Flowthrombosis while apyrase lacks efficacy under flow conditions. Integr
Biol (Camb). 2:183–192.
68. Eckstein, E. C., A. W. Tilles, and F. J. Millero, 3rd. 1988. Conditions
for the occurrence of large near-wall excesses of small particles during
blood flow. Microvasc. Res. 36:31–39.
69. Leiderman, K., and A. L. Fogelson. 2013. The influence of hindered
transport on the development of platelet thrombi under flow. Bull.
Math. Biol. 75:1255–1283.
70. Tosenberger, A., N. Bessonov, and V. Volpert. 2015. Influence of fibrin-
ogen deficiency on clot formation in flow by hybrid model. Math.
Model. Nat. Phenom. 10:36–47.
71. Bolliger, D., F. Szlam, ., K. A. Tanaka. 2009. Finding the optimal
concentration range for fibrinogen replacement after severe haemodilu-
tion: an in vitro model. Br. J. Anaesth. 102:793–799.
72. Mitrophanov, A. Y., A. S. Wolberg, and J. Reifman. 2014. Kinetic
model facilitates analysis of fibrin generation and its modulation by
clotting factors: implications for hemostasis-enhancing therapies.
Mol. Biosyst. 10:2347–2357.
73. Scho¨chl, H., L. Forster, ., W. Voelckel. 2010. Use of rotation
thromboelastometry (ROTEM) to achieve successful treatment of
polytrauma with fibrinogen concentrate and prothrombin complex
concentrate. Anaesthesia. 65:199–203.
74. Scho¨chl, H., U. Nienaber, ., C. Solomon. 2010. Goal-directed coag-
ulation management of major trauma patients using thromboelastome-
try (ROTEM)-guided administration of fibrinogen concentrate and
prothrombin complex concentrate. Crit. Care. 14:R55.
75. Mitrophanov, A. Y., and J. Reifman. 2011. Kinetic modeling sheds light
on the mode of action of recombinant factor VIIa on thrombin gener-
ation. Thromb. Res. 128:381–390.
76. Falati, S., P. Gross, ., B. Furie. 2002. Real-time in vivo imaging of
platelets, tissue factor and fibrin during arterial thrombus formation
in the mouse. Nat. Med. 8:1175–1181.
77. Ivanciu, L., S. Krishnaswamy, and R. M. Camire. 2012. Imaging coag-
ulation reactions in vivo. Thromb. Res. 129 (Suppl 2):S54–S56.
78. Kim, O. V., Z. Xu, ., M. S. Alber. 2013. Fibrin networks regulate
protein transport during thrombus development. PLOS Comput. Biol.
9:e1003095.
79. Muthard, R. W., and S. L. Diamond. 2012. Blood clots are rapidly
assembled hemodynamic sensors: flow arrest triggers intraluminal
thrombus contraction. Arterioscler. Thromb. Vasc. Biol. 32:2938–2945.
80. Welsh, J. D., T. J. Stalker,., L. F. Brass. 2014. A systems approach to
hemostasis: 1. The interdependence of thrombus architecture and
agonist movements in the gaps between platelets. Blood. 124:1808–
1815.
81. Xu, Z., S. Christley, ., M. Alber. 2012. Multiscale model of fibrin
accumulation on the blood clot surface and platelet dynamics.Methods
Cell Biol. 110:367–388.
82. Stalker, T. J., E. A. Traxler,., L. F. Brass. 2013. Hierarchical organi-
zation in the hemostatic response and its relationship to the platelet-
signaling network. Blood. 121:1875–1885.83. Tokarev, A. A., A. A. Butylin, and F. I. Ataullakhanov. 2011. Platelet
adhesion from shear blood flow is controlled by near-wall rebounding
collisions with erythrocytes. Biophys. J. 100:799–808.
84. Reed, G. L., M. L. Fitzgerald, and J. Polga´r. 2000. Molecular mecha-
nisms of platelet exocytosis: insights into the ‘‘secrete’’ life of throm-
bocytes. Blood. 96:3334–3342.
85. Lages, B. 1986. In vitro platelet responses: dense granule secretion. In
Platelet Responses and Metabolism Vol. I: Responses. H. Holmsen,
editor. CRC Press, Boca Raton, FL.
86. Zhang, J., P. C. Johnson, and A. S. Popel. 2008. Red blood cell aggre-
gation and dissociation in shear flows simulated by lattice Boltzmann
method. J. Biomech. 41:47–55.
87. Jafari, A., S. M. Mousavi, and P. Kolari. 2008. Numerical investigation
of blood flow. Part I: In microvessel bifurcations. Commun. Nonlinear
Sci. Numer. Simul. 13:1615–1626.
88. Papaioannou, T. G., and C. Stefanadis. 2005. Vascular wall shear stress:
basic principles and methods. Hellenic J. Cardiol. 46:9–15.
89. Mann, K. G., M. E. Nesheim, ., S. Krishnaswamy. 1990. Surface-
dependent reactions of the vitamin K-dependent enzyme complexes.
Blood. 76:1–16.
90. Mann, K. G., E. G. Bovill, and S. Krishnaswamy. 1991. Surface-depen-
dent reactions in the propagation phase of blood coagulation. Ann. N. Y.
Acad. Sci. 614:63–75.
91. Morrissey, J. H. 1995. Tissue factor modulation of factor VIIa activity:
use in measuring trace levels of factor VIIa in plasma. Thromb.
Haemost. 74:185–188.
92. Novotny, W. F., S. G. Brown,., G. J. Broze, Jr. 1991. Plasma antigen
levels of the lipoprotein-associated coagulation inhibitor in patient
samples. Blood. 78:387–393.
93. Scandura, J. M., S. S. Ahmad, and P. N. Walsh. 1996. A binding site
expressed on the surface of activated human platelets is shared by fac-
tor X and prothrombin. Biochemistry. 35:8890–8902.
94. Brass, L. F., M. Ahuja, ., J. A. Hoxie. 1994. The human platelet
thrombin receptor. Turning it on and turning it off. Ann. N. Y. Acad.
Sci. 714:1–12.
95. Walsh, P. N., and A. H. Schmaier. 1994. Platelet-coagulant protein
interactions. InHemostasis and Thrombosis: Basic Principles and Clin-
ical Practice, 3rd ed. R. W. Colman, J. Hirsh, V. J. Marder, and
E. W. Salzman, editors. Lippincott, Philadelphia, PA, pp. 629–651.
96. Ahmad, S. S., J. M. Scandura, and P. N. Walsh. 2000. Structural and
functional characterization of platelet receptor-mediated factor VIII
binding. J. Biol. Chem. 275:13071–13081.
97. Ahmad, S. S., R. Rawala-Sheikh, and P. N. Walsh. 1989. Comparative
interactions of factor IX and factor IXa with human platelets. J. Biol.
Chem. 264:3244–3251.
98. Mann, K. G., S. Krishnaswamy, and J. H. Lawson. 1992. Surface-
dependent hemostasis. Semin. Hematol. 29:213–226.Biophysical Journal 110, 1869–1885, April 26, 2016 1885
